• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.07% Nasdaq Up0.06%

    Hospira Inc. (HSP)

    -NYSE
    62.24 Down 0.20(0.32%) 10:57AM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Hospira Inc.
    275 North Field Drive
    Lake Forest, IL 60045
    United States - Map
    Phone: 224-212-2000
    Website: http://www.hospira.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drugs - Generic
    Full Time Employees:17,000

    Business Summary 

    Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprises Biosimilars that include Retacrit, a biosimilar erythropoietin, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent; and Inflectra, a biosimilar infliximab for the treatment of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and psoriasis. In addition, it offers medication management products, including infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, the company provides intravenous solutions and nutritional products; and contract manufacturing services, as well as develops proprietary pharmaceutical products, such as Dyloject, a post-operative pain management drug. It serves hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Hospira Inc.

    Corporate Governance 
    Hospira Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 9. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 7; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. F. Michael Ball , 58
    Chief Exec. Officer, Director and Member of Science & Technology Committee
    3.09M0.00
    Mr. Thomas E. Werner , 57
    Chief Financial Officer and Sr. VP of Fin.
    843.00K0.00
    Mr. Matthew R. Stober , 46
    Sr. VP of Operations
    816.00K0.00
    Dr. Sumant Ramachandra M.D., Ph.D., 45
    Chief Scientific Officer and Sr. VP
    873.00K0.00
    Mr. Richard J. Davies , 52
    Chief Commercial Officer and Sr. VP
    865.00K0.00
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders